ROKIT Healthcare Inc, a regenerative medicine company focused on the development of novel regenerative therapeutic strategies using three-dimensional (3D) biofabrication technologies for treatment of various medical conditions including dermatological, orthopedic, and autoimmune disorders, announced a novel application of dermal regeneration platform using autologous cells and its proprietary 3D bioprinter INVIVO®. This new regenerative therapeutic platform will be further studied in clinical settings for patients in need of treatment for damages suffered from dermal scarring. For more information see the IDTechEx report on 3D Bioprinting 2018-2028.
Skin scarring is one of the most common medical conditions that can arise after almost every dermal injury, some of which can cause considerable physical, aesthetic, psychological and social problems that result in millions of elective operations and operations after trauma.
ROKIT's treatment strategy uses INVIVO®, ROKIT's proprietary 3D bioprinter, and patient's autologous tissues and cells to "print" a dermal patch graft to treat scarred lesions. Combination of the 3D printing technology that allows for uniform and equal-density distribution of the cells and the use of patient's autologous tissue/cells can lead to rapid migration of keratinocytes and neovascularization at the wound site, resulting in effective regeneration of the skin at treated lesion.
"It is a novel way of overcoming some of the most pronounced limitations associated with traditional stem cell therapy. The current practice of directly injecting expanded or cultured stem cells using syringes severely limits cell viability and accurate, uniformly distributed delivery of effective stem cells unto the disease area," stated Seok-Hwan You, Chief Executive Officer of ROKIT Healthcare. "Utilizing 3D bioprinting techniques allows for effective delivery of autologous cells unto the wound site, minimizing cell loss and greatly enhancing cell viability and proliferation."
ROKIT will further evaluate the effectiveness of the treatment in investigator-initiated clinical studies, which will initially open in Korea, with expansion to multiple countries worldwide. The company plans to expand the application of this novel treatment strategy to other dermatological conditions such as burns, pressure ulcers, and diabetic foot ulcers.
Source: ROKIT Healthcare
Top image: Wikipedia